


2022 Impact Report



SWOG's 2022 productivity becomes clearer when you consider that, in addition to the trials we've already activated this year, we're poised to activate 11 other protocols in the first quarter of 2023 alone. *And*, these include several groundbreaking designs likely to set new standards for future NCTN trials.



Charles D. Blanke, MD
— Charles D. Blanke, MD
Chair, SWOG Cancer Research Network



Our new kidney cancer patient advocate Laura Esfeller, MA, can testify to the impact of SWOG trials. Diagnosed with stage IV papillary renal cell carcinoma, she went on to join the S1500 PAMPET trial. She had a complete response to cabozantinib, a drug the PAMPET trial would eventually set as the new standard of care for her disease.



We named Don Dizon, MD, SWOG's first vice chair for diversity, equity, inclusion, and professional integrity. He provides strategic vision and direction as we work to make our leadership and membership more diverse and our trial enrollment more representative.

70 New Member Sites



Our Data

- **7** SWOG trials activated
- **6** SWOG trials closed
- **24** SWOG clinical and translational concepts reviewed by leadership
- **13** requests for trial data approved
- **2,636** patients enrolled on all SWOG-run trials, not counting screening registrations
- **76** journal articles published
- **40%** published in high impact factor journals
- **85** oral or poster presentations made
- **25%** of presentations made were oral



Our patient advocate committee not only diversified their own ranks, in part by welcoming new community advocates representing historically underrepresented groups, they also continued to be central to our efforts to enhance diversity, equity, and inclusion throughout SWOG and across our trials.

Our Highlights

- **We presented several sets of practice-changing results at professional meetings this year.** At ASCO, where we gave a record 36 presentations (22 SWOG-led), Karen Reckamp, MD, MS, presented results from Lung-MAP sub-study S1800A that have led to an FDA "breakthrough designation" for the drug immunotherapy tested. Also at ASCO, Kari Kendra, MD, PhD, presented findings from the S1512 trial of neoadjuvant immunotherapy in patients with desmoplastic melanoma – results that have changed clinical practice in that disease. In September, Sapna Patel, MD, delivered another set of practice-changing findings in melanoma, these from the S1801 trial, at a Presidential Symposium at the annual ESMO Congress in Paris.
- **We showed (again) that NCTN research has impact, but also that that impact comes at a very reasonable cost.** Work led by Joseph Unger, PhD, reported that the 14.2 million life-years added by 40 years of positive cooperative group trial results required a federal investment of only about \$326 per life-year gained.
- **We convened a diversity, equity, and inclusion (DEI) monitoring committee this year,** charged with regularly reviewing trial diversity and with monitoring plans for ensuring enrolled participants represent the patient populations they stand in for. The monitoring committee complements the work of our DEI champions now integrated into five pilot research committees.
- **We launched a new learning management system** fully integrated with SWOG's member directory, which allows for role-driven training catalogs, an improved learner interface, and a vastly improved ability to deliver content and track the completion of web-based training programs.
- To make information about our trials more accessible to potential participants in those trials, we started publishing **patient-friendly summaries and social media toolkits** for every new trial. We'll soon have them for all ongoing trials as well.
- **Building on the positive S1800A results reported at ASCO in June, we developed the follow-on phase III S2302 Pragmatica-Lung protocol in near-record time.** With some key guidance from the FDA, this landmark design features dramatically simplified eligibility criteria and a radically reduced workload for clinical sites. Poised to activate in the first days of 2023, the trial promises to be a model for many streamlined drug registration studies to come.
- **We launched a new generation of NCI precision medicine master protocols with activation of the S2101 pilot study for ImmunoMATCH.** SWOG is the lead group on the screening protocol for this study and on the screening protocol for the MyeloMATCH study in myeloid malignancies, which is expected to launch in early 2023.




We welcomed **Jhanelle Gray, MD**, as our new lung committee chair and **Virginia Sun, PhD, RN**, as our newest executive officer, overseeing palliative & end-of-life care research and cancer survivorship research.

THE HOPE FOUNDATION FOR CANCER RESEARCH

MAKING GOOD ON Progress Promised

In last year's Impact Report, we highlighted two of our funding programs designed to better serve diverse patient populations. This year, we're pleased to share how those efforts have progressed:

- First, we expanded our support for veterans.** In its initial eight years, our VA Integration Support program funded 21 grants to Veterans Affairs Medical Centers across the country. Seeing considerable success, program leaders proposed a broader project, the VA Storefront Support Program – a larger award to a single VA site that will serve as a support hub for neighboring sites. The South Texas Veterans Health Care System, located in San Antonio, was awarded the first storefront grant in 2022. We look forward to learning how these VA medical centers collectively improve critical cancer care for veterans in the years ahead.
- Second, we ramped up our international research efforts.** The SWOG Latin America Initiative (SLAI) has grown impressively. Beyond its spring and fall symposia, the SLAI re-launched its clinical trials training course after a COVID-19 pause; the latest course took place in Montevideo, Uruguay. Now under the leadership of Dr. Mariana Chavez Mac Gregor, the SLAI has accrued a significant number of patients to SWOG studies and is working to expand access to NCI-sponsored trials across Latin America.
- More broadly, we've helped SWOG bring aboard its first vice chair for diversity, equity, inclusion, and professional integrity (DEI): Dr. Don Dizon.** As noted above, Dr. Dizon's position as a vice chair ensures that DEI efforts remain a central, integrated focus of SWOG's strategy to improve research outcomes.
- We're pleased to support an expanded patient advocate team, too.** We've increased funding for new patient advocate roles representing numerous underserved populations, including rural patients, older patients, and patients from the LGBTQ+ community. These additional members enhance representation of the patient perspective across committees and their clinical trials.
- As we look ahead to our 30th anniversary, we're astounded by what we've accomplished, thanks to the generosity of our donors, the dedication of our staff, and the vision of our board.** It's humbling to build upon the work of so many before us. It's equally thrilling to dedicate our time to furthering the aims of today's best and brightest. After supporting an entire generation of cancer researchers and trial participants, we're ready to drive efforts forward in the next one.



With respect and appreciation,
Johanna R. Horn
Johanna R. Horn
President & CEO
Raymond U. Osarogiabon
Raymond U. Osarogiabon, MD
Board Chair